SLN logo

SLN Silence Therapeutics plc

NASDAQ Global Market · Biotechnology · Healthcare

$19.82
-0.01 (-0.03%)

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precis…

Market Cap: $936.41Mwww.silence-therapeutics.com

Price

$11.95+67.60%
$5.77$7.87$9.97$12.07
May 1Aug 7

Social Signal Score

61
5d
—
30d
—
60d
60
3 mentions
+0.0%
90d
63
4 mentions
+0.0%
news: 4

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 1Sell 1Strong Sell 0
Avg price target$20+0.9%
Low $20Median $20High $20
Current Consensus

Revenue

$0.00-100.00%
$0.00$8.11M$16.22M$24.33M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.91
$-1.61–$-0.45
3 analysts
FY2026
$-0.36
$-0.50–$-0.16
3 analysts
FY2027
$-0.55
$-0.81–$-0.22
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Iain Gladstone Ross
Sector
Healthcare
Industry
Biotechnology
Employees
88
Beta
1.34
Country
GB
Piotroski score
2 / 9 (Weak)
Altman Z-score
3.89
www.silence-therapeutics.com